<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>389-OMEPRAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OMEPRAZOLE" rxcui="7646">
<ATC code="A02BC01" />
<ATC code="A02BD05" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and monitoring of the digoxinemia, particularly with an older patient. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>389-OMEPRAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="OMEPRAZOLE" rxcui="7646">
<ATC code="A02BC01" />
<ATC code="A02BD05" />
<ATC code="A02BD01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TACROLIMUS" rxcui="42316">
<ATC code="D11AH01" />
<ATC code="L04AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the blood concentrations of the tacrolimus</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Blood concentration dosage of the tacrolimus, testing of the renal function and adjustment of the dosage during the administration of the substances together and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
